If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

I am a dedicated and compassionate medical oncologist with a particular interest in genitourinary and
gastrointestinal cancers. I have five years of Consultant Medical Oncology experience, predominantly treating genitourinary and lower gastrointestinal cancers. I have a particularly strong research background, with extensive experience as an investigator in clinical trials and translational research. I have completed a Masters in Clinical Epidemiology and have submitted a PhD in translational prostate cancer. Through working at the NHMRC Clinical Trials Centre and for the ANZUP Trials Group, I have developed trial management experience in large Phase 2 and 3 trials and have established solid research connections and collaborative networks.

Fingerprint Dive into the research topics where Alison Zhang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Heartburn Medicine & Life Sciences
Fundoplication Medicine & Life Sciences
Castration Medicine & Life Sciences
Clinical Protocols Medicine & Life Sciences
Prostatectomy Medicine & Life Sciences
Sarcoma Medicine & Life Sciences
Multicenter Studies Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Outputs 2008 2019

  • 76 Citations
  • 4 h-Index
  • 8 Article

An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy

Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., Butler, L. M., Knudsen, K., Comstock, C., Rasiah, K., Grogan, J., Mahon, K. L., Bianco-Miotto, T., Ricciardelli, C., Böhm, M., Henshall, S., Delprado, W., Stricker, P., Horvath, L. G. & Kench, J. G., 1 Mar 2019, In : International Journal of Cancer. 144, 5, p. 1151-1159 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatectomy
Prostatic Neoplasms
Biomarkers
Neoplasm Metastasis
Recurrence

Enzalutamide with standard first-line therapy in metastatic prostate cancer

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D. W. & 14 othersNeil Reaume, M., Sandhu, S. K., Tan, A., Hsiang Tan, T., Thomson, A., Tu, E., Vera-Badillo, F., Williams, S. G., Yip, S., Zhang, A. Y., Zielinski, R. R., Sweeney, C. J., ENZAMET Trial Investigators & The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP), 11 Jul 2019, In : New England Journal of Medicine. 381, 2, p. 121-131 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Disease-Free Survival
docetaxel
Therapeutics
Testosterone

Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer

Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., Lin, H. M., Aishah, A., Varney, B., Liu-Fu, F., Lee, L. S., Nagarajan, S. R., Shearer, R. F., Hardie, R. A., Raftopulos, N. L., Kakani, M. S., Saunders, D. N., Holst, J., Horvath, L. G., Butler, L. M. & 1 othersHoy, A. J., Apr 2019, In : Molecular Cancer Research. 17, 4, p. 949-962 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Fatty Acids
Lipids
Palmitates
Triglycerides

TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

Hofman, M. S., Emmett, L., Violet, J., Y. Zhang, A., Lawrence, N. J., Stockler, M., Francis, R. J., Iravani, A., Williams, S., Azad, A., Martin, A., McJannett, M. & ANZUP TheraP team, 1 Nov 2019, In : BJU international. 124, S1, p. 5-13 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Castration
Clinical Protocols
Prostatic Neoplasms
Clinical Trials
docetaxel

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer

Zhang, A. Y., Grogan, J. S., Mahon, K. L., Rasiah, K., Sved, P., Eisinger, D. R., Boulas, J., Vasilaris, A., Henshall, S. M., Stricker, P. D., Kench, J. G. & Horvath, L. G., Aug 2017, In : Annals of Oncology. 28, 8, p. 1903-1909 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Activities 2012 2018

  • 7 Oral presentation

An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy

Alison Zhang (Speaker)
8 Feb 201810 Feb 2018

Activity: Talk or presentationOral presentation

A prospective multi-centre Phase III validation study of AZGP1 as a biomarker in localized prostate cancer

Alison Zhang (Speaker)
13 Feb 201715 Feb 2017

Activity: Talk or presentationOral presentation

Chemotherapy reduces time to development of radiation-induced sarcomas

Alison Zhang (Speaker)
2 Jun 20176 Jun 2017

Activity: Talk or presentationOral presentation

Toxicity-adjusted dose of sunitinib gives low-intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer

Alison Zhang (Speaker)
30 May 20143 Jun 2014

Activity: Talk or presentationOral presentation

Metformin to preventing androgen deprivation therapy-induced insulin resistance and the metabolic syndrome

Alison Zhang (Speaker)
27 Sep 20131 Oct 2013

Activity: Talk or presentationOral presentation